Monday, March 23, 2026

Hims & Hers shifts US weight loss strategy with Novo Nordisk deal

Hims & Hers Health has announced a strategic shift in its US weight loss business. The company said it is aligning its domestic approach more closely with its international model, starting with a collaboration with Novo Nordisk.

Emphasis on FDA-approved GLP-1 medicines

According to the company, US customers seeking GLP-1-based weight loss care are expected to get access to a broader range of FDA-approved medications. Hims & Hers also said it intends to continue offering compounded semaglutide only on a limited basis, where a provider determines a compounded product is clinically necessary.

As part of the change, the company said it will stop advertising compounded GLP-1 offerings on its platform and in marketing. Existing patients are expected to have an option to transition to FDA-approved medicines when providers consider it clinically appropriate.

Ozempic and Wegovy planned for the platform

Hims & Hers said its agreement with Novo Nordisk will bring Ozempic (semaglutide) injections in 0.5 mg, 1 mg, and 2 mg, as well as Wegovy (semaglutide) pills and injections, to the platform later this month. The company listed Wegovy injections at 1.7 mg and 2.4 mg and Wegovy tablets at 1.5 mg, 4 mg, 9 mg, and 25 mg.

Over the coming months, Hims & Hers said it will inform US weight loss customers about the expanded set of FDA-approved options and support transitions where clinicians deem it appropriate. The companies also indicated they may work together on additional products as they become available.

Support services and litigation update

Hims & Hers said it will continue to provide support services alongside treatment, including access to providers, nutrition guidance, and ongoing clinical check-ins.

At the same time, the company said Novo Nordisk is dismissing its lawsuit against Hims & Hers without prejudice.

More information is available via the company’s newsroom at news.hims.com.